- Home
- CASI vs GDTC Comparison
CASI vs GDTC Comparison
Compare CASI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- GDTC
- Stock Information
- Founded
- CASI 1991
- GDTC 2018
- Country
- CASI China
- GDTC Singapore
- Employees
- CASI N/A
- GDTC N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- GDTC Health Care
- Exchange
- CASI Nasdaq
- GDTC Nasdaq
- Market Cap
- CASI 29.7M
- GDTC 28.0M
- IPO Year
- CASI 1996
- GDTC 2023
- Fundamental
- Price
- CASI $1.89
- GDTC $2.32
- Analyst Decision
- CASI Strong Buy
- GDTC Buy
- Analyst Count
- CASI 1
- GDTC 1
- Target Price
- CASI $4.00
- GDTC $5.00
- AVG Volume (30 Days)
- CASI 7.1K
- GDTC 8.6K
- Earning Date
- CASI 05-16-2025
- GDTC 01-01-0001
- Dividend Yield
- CASI N/A
- GDTC N/A
- EPS Growth
- CASI N/A
- GDTC N/A
- EPS
- CASI N/A
- GDTC N/A
- Revenue
- CASI $31,368,000.00
- GDTC $368,838.00
- Revenue This Year
- CASI N/A
- GDTC $5.37
- Revenue Next Year
- CASI N/A
- GDTC N/A
- P/E Ratio
- CASI N/A
- GDTC N/A
- Revenue Growth
- CASI 8.39
- GDTC N/A
- 52 Week Low
- CASI $1.64
- GDTC $1.20
- 52 Week High
- CASI $7.67
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CASI 47.25
- GDTC 51.17
- Support Level
- CASI $1.77
- GDTC $2.21
- Resistance Level
- CASI $1.98
- GDTC $2.45
- Average True Range (ATR)
- CASI 0.10
- GDTC 0.12
- MACD
- CASI 0.01
- GDTC 0.02
- Stochastic Oscillator
- CASI 54.55
- GDTC 52.29
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.